Key Financial Inc Has $2.08 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Key Financial Inc trimmed its stake in Pfizer Inc. (NYSE:PFE) by 0.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 72,018 shares of the biopharmaceutical company’s stock after selling 477 shares during the quarter. Key Financial Inc’s holdings in Pfizer were worth $2,084,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. bought a new stake in Pfizer during the 1st quarter valued at $315,000. Norden Group LLC lifted its stake in Pfizer by 26.8% during the 1st quarter. Norden Group LLC now owns 30,336 shares of the biopharmaceutical company’s stock valued at $842,000 after acquiring an additional 6,404 shares during the period. Connecticut Wealth Management LLC lifted its stake in Pfizer by 11.8% during the 1st quarter. Connecticut Wealth Management LLC now owns 18,279 shares of the biopharmaceutical company’s stock valued at $507,000 after acquiring an additional 1,936 shares during the period. Sippican Capital Advisors lifted its stake in Pfizer by 21.5% during the 1st quarter. Sippican Capital Advisors now owns 82,762 shares of the biopharmaceutical company’s stock valued at $2,297,000 after acquiring an additional 14,618 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. lifted its stake in Pfizer by 6.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 137,125 shares of the biopharmaceutical company’s stock valued at $3,805,000 after acquiring an additional 7,718 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 0.06% of the stock is owned by corporate insiders.

Pfizer Price Performance

Shares of PFE traded down $0.21 during trading hours on Friday, hitting $28.09. 46,894,562 shares of the company were exchanged, compared to its average volume of 37,243,188. The company has a market capitalization of $159.18 billion, a PE ratio of 37.96, a PEG ratio of 0.90 and a beta of 0.67. The firm has a fifty day simple moving average of $29.03 and a 200-day simple moving average of $28.57. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. Pfizer Inc. has a one year low of $25.20 and a one year high of $31.54.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. The business’s quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.17) EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.98%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is presently 227.03%.

Analysts Set New Price Targets

A number of research firms have commented on PFE. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday. Citigroup started coverage on Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 target price for the company. Barclays lifted their price objective on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Wells Fargo & Company increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, UBS Group upped their price objective on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $33.58.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.